https://firstascentbiomedical.com/fabs-cto-noah-berlow-is-combining-biology-engineering-to-speed-drug-development-nature/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/probabilistic-modeling-of-personalized-drug-combinations/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/functionally-defined-therapeutic-targets-in-diffuse-intrinsic-pontine-glioma/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/machine-learning-for-rhabdomyosarcoma-histopathology/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/machine-learning-for-rhabdomyosarcoma-histopathology-2/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/in-vitro-benchmarking-of-nf-%ce%bab-inhibitors/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/defining-the-extracellular-matrix-of-rhabdomyosarcoma/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/volasertib-preclinical-activity-in-high-risk-hepatoblastoma/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/refractory-alveolar-rhabdomyosarcoma-in-an-11-year-old-male/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/defining-an-embryonal-rhabdomyosarcoma-endotype/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/sensitization-of-osteosarcoma-to-irradiation-by-targeting-nuclear-fgfr1/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/preclinical-rationale-for-entinostat-in-embryonal-rhabdomyosarcoma/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/bromodomain-4-inhibition-leads-to-mycn-downregulation-in-wilms-tumor/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/receptor-driven-invasion-profiles-in-diffuse-intrinsic-pontine-glioma/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/functional-impact-of-a-germline-ret-mutation-in-alveolar-rhabdomyosarcoma/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/functional-genomic-analysis-of-epithelioid-sarcoma-reveals-distinct-proximal-and-distal-subtype-biology/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/preclinical-therapeutics-ex-ovo-quail-eggs-as-a-biomimetic-automation-ready-xenograft-platform/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/igf1r-as-a-key-target-in-high-risk-metastatic-medulloblastoma/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/probabilistic-boolean-modeling-of-pre-clinical-tumor-models-for-biomarker-identification-in-cancer-drug-development/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/design-considerations-of-an-il13r%ce%b12-antibody-drug-conjugate-for-difuse-intrinsic-pontine-glioma/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/preclinical-testing-of-the-glycogen-synthase-kinase-3%ce%b2-inhibitor-tideglusib-for-rhabdomyosarcoma/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/combination-therapy-design-for-maximizing-sensitivity-and-minimizing-toxicity/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/deep-functional-and-molecular-characterization-of-a-high-risk-undifferentiated-pleomorphic-sarcoma/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/il-13-receptors-as-possible-therapeutic-targets-in-diffuse-intrinsic-pontine-glioma/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/target-inhibition-maps-based-on-responses-to-kinase-inhibitors/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/an-integrated-approach-to-anti-cancer-drug-sensitivity-prediction/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/elucidating-the-transcriptional-program-of-feline-injection-site-sarcoma-using-a-cross-species-mrna-sequencing-approach/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/the-hdac3-smarca4-mir-27a-axis-promotes-expression-of-the-pax3foxo1-fusion-oncogene-in-rhabdomyosarcoma/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/undifferentiated-small-round-cell-sarcoma-in-a-young-male-a-case-report/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/case-report-for-an-adolescent-with-germline-ret-mutation-and-alveolar-rhabdomyosarcoma/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/probabilistic-modeling-of-personalized-drug-combinations-from-integrated-chemical-screen-and-molecular-data-in-sarcoma/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/rb1-loss-modifies-but-does-not-initiate-alveolar-rhabdomyosarcoma/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/integration-of-genomic-transcriptomic-and-functional-profiles-of-aggressive-osteosarcomas-across-multiple-species/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/a-new-approach-for-prediction-of-tumor-sensitivity-to-targeted-drugs-based-on-functional-data/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/generation-of-intervention-strategy-for-a-genetic-regulatory-network-represented-by-a-family-of-markov-chains/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/functional-genomics-of-human-clear-cell-sarcoma-genomic-transcriptomic-and-chemical-biology-landscape-for-clear-cell-sarcoma/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/inference-of-dynamic-biological-networks-based-on-responses-to-drug-perturbations/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/a-kinase-inhibition-map-approach-for-tumor-sensitivity-prediction-and-combination-therapy-design-for-targeted-drugs/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/a-high-throughput-in-vitro-drug-screen-in-a-genetically-engineered-mouse-model-of-diffuse-intrinsic-pontine-glioma-identifies-bms-754807-as-a-promising-therapeutic-agent/2026-10-26T15:19:59+00:00https://firstascentbiomedical.com/ex-vivo-drug-sensitivity-testing-and-multi-omics-profiling/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/functional-precision-medicine-platform-identifies-effective-treatments/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/functional-precision-medicine-leads-to-better-cancer-treatments/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/asco-2024-abstract-presentations/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/asco2024-press-release/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/biomarker-development-for-pharmaceutical-companies-and-patients/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/asco-2024-clinical-results/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/clinical-results-published-in-nature-medicine/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/cancerx-selects-first-ascent-biomedical-into-2025-driving-innovation-in-oncology-cohort/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/first-ascent-biomedical-awarded-florida-cancer-innovation-fund-grant/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/community-collaboration-yields-new-labs-new-program-new-approach-to-cancer-care-to-region/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/standing-ovation-at-tedxmiami-dr-diana-azzam-highlights-miami-based-partnership-that-gave-one-child-a-second-chance-at-life/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/first-ascent-biomedical-and-fight-colorectal-cancer-foundation-announce-groundbreaking-study-to-advance-precision-oncology-for-colorectal-cancer-patients/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/innovation-in-cancer-care-a-focus-on-patient-centered-solutions-and-research-acceleration/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/reachmd-redefining-cancer-care-with-functional-precision-medicine/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/how-functional-precision-medicine-could-be-the-future-of-cancer-care-dr-diana-azzam-tedxmiami/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/childhood-cancer-awareness-month-eries-innovative-breakthrough/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/father-turns-tragedy-into-mission-to-change-childhood-cancer-treatment/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/ai-driven-platform-aims-to-bring-personalized-cancer-treatment-to-more-patients/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/mother-of-a-two-time-cancer-survivor-andria-parks-shares-breast-cancer-treatment-options/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/first-ascent-biomedical-opens-fpm-cancer-lab-in-miami-welcomes-world-class-clinical-leadership/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/andria-parks-of-first-ascent-biomedical-5-things-everyone-needs-to-know-about-cancer/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/the-next-leap-in-oncology-how-real-world-biology-and-ai-are-changing-everything/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/functional-precision-medicine-beyond-the-standard-of-care/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/from-consensus-oncology-to-individualized-biology-how-ai-enabled-functional-precision-medicine-could-rewrite-cancer-care/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/how-ai-driven-functional-precision-medicine-unlocks-personalized-cancer-therapy/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/right-to-try-modernization-amendment/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/raymond-rodriguez-torres-appointed-first-ascent-biomedical-new-president-to-scale-functional-precision-oncology/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/asco-clinical-notice-asco-clarification-on-the-status-of-functional-precision-medicine-fpm/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/first-ascent-biomedical-responds-to-asco-clarification-on-functional-precision-medicine/2026-10-26T15:19:58+00:00https://firstascentbiomedical.com/lucem-health-announces-innovation-collaborative-with-first-ascent-bringing-ai-to-the-front-lines/2026-10-26T15:19:59+00:00